Publications des scientifiques de l'IRD

Monleau M., Plantier J. C., Peeters Martine. (2010). HIV contamination of commercial PCR enzymes raises the importance of quality control of low-cost in-house genotypic HIV drug resistance tests. Antiviral Therapy, 15 (1), p. 121-126. ISSN 1359-6535.

Titre du document
HIV contamination of commercial PCR enzymes raises the importance of quality control of low-cost in-house genotypic HIV drug resistance tests
Année de publication
2010
Type de document
Article référencé dans le Web of Science WOS:000276528900013
Auteurs
Monleau M., Plantier J. C., Peeters Martine
Source
Antiviral Therapy, 2010, 15 (1), p. 121-126 ISSN 1359-6535
Background: Low-cost in-house technologies for genotypic drug resistance testing use reagents with quality labels for research only. Here, we report on the results of PCR amplifications in negative-controls that were observed in two independent laboratories. Methods: Positive PCR amplifications of protease and reverse transcriptase fragments for genotypic drug resistance testing of HIV on dried blood and/or plasma spots were observed on negative-control samples and were analysed in detail by PCR and sequence and phylogenetic analyses to identify the origin of the PCR contamination. Results: Detailed analysis revealed that the RT-PCR enzymes were contaminated with an HIV-based vector commercialized by the same company. Conclusions: These observations show the need to implement quality control steps that verify for the absence of HIV in new reagent batches because this can significantly compromise molecular diagnosis of HIV and genotypic drug resistance tests using in-house protocols.
Plan de classement
Santé : généralités [050]
Localisation
Fonds IRD [F B010081632]
Identifiant IRD
fdi:010081632
Contact